Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.07.006 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Ryohei Tanigawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Clinical Development Department, Kowa Company Ltd., Tokyo, Japan (Mr Tanigawa); Department of Hepatology, Division of Metabolism, Faculty of M…. Hauptthemen laut MEDLINE: Benzoxazoles, Butyrates, Cholesterol Ester Storage Disease, Cholesterol Ester Transfer Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kowa Company Ltd.
Abstract (Originalsprache)
Cholesteryl ester transfer protein (CETP) deficiency is a representative molecular abnormality in familial hyperalphalipoproteinemia, a hereditary disorder of lipid metabolism characterized by markedly elevated plasma high-density lipoprotein cholesterol (HDL-C) levels. In this condition, dysfunction of CETP, which mediates the transfer of cholesteryl esters from HDL particles to apolipoprotein (Apo)B-containing lipoproteins, leads to the abnormal accumulation of HDL-C. These HDL particles are unusually large and enriched in cholesteryl esters, ApoCIII, and ApoE, whereas low-density lipoprotein (LDL) particles are small, depleted of cholesteryl esters, and enriched in triglycerides. Both HDL and LDL particles in CETP deficiency are functionally abnormal. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, has consistently been demonstrated in clinical trials to increase HDL-C levels by 16% to 22% in patients with dyslipidemia and low baseline HDL-C. Herein, we describe the unexpected finding of a marked reduction in HDL-C levels in a patient with CETP deficiency following pemafibrate treatment. To better understand this paradoxical response, we analyzed the patient's clinical data and investigated potential mechanisms underlying pemafibrate's effects on HDL metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Clinical Development Department, Kowa Company Ltd., Tokyo, Japan (Mr Tanigawa); Department of Hepatology, Division of Metabolism, Faculty of Medicine, Saga University, Saga, Japan (Mr Tanigawa and Dr Takahashi).…
- Department of Diabetes and Endocrinology, NTT Medical center Sapporo, Hokkaido, Japan (Dr Nagai).
- Department of Hepatology, Division of Metabolism, Faculty of Medicine, Saga University, Saga, Japan (Mr Tanigawa and Dr Takahashi).
- Clinical Data Science Department, Kowa Company Ltd., Tokyo, Japan (Dr Suganami).
- Department of Cardiology, Rinku General Medical Center, Osaka, Japan (Dr Yamashita).
Förderung
- Kowa Company Ltd
Zitieren
APA
Tanigawa, R., Nagai, S., Takahashi, H., Suganami, H., & Yamashita, S. (2025). Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.07.006
Vancouver
Tanigawa R, Nagai S, Takahashi H, Suganami H, Yamashita S. Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.07.006
BibTeX
@article{Tanigawa2025,
author = {Tanigawa, Ryohei and Nagai, So and Takahashi, Hirokazu and Suganami, Hideki and Yamashita, Shizuya},
title = {Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.07.006}
}
EUVIMED